News - tivantinib

Filter

Current filters:

tivantinib

Popular Filters

Daiichi Sankyo returns rights to ArQule for global AKT program

03-04-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) has returned worldwide rights for the development and…

ARQ 092ARQ 197ArQuleDaiichi SankyoLicensingOncologyPharmaceuticalResearchtivantinib

Another disappointment with Daiichi Sankyo and ArQule's tivantinib

14-01-2013

US drug developer ArQule (Nasdaq: ARQL) saw its shares plunge 23% to $2.25 in premarket trading on Friday,…

ArQuleDaiichi SankyoOncologyPharmaceuticalResearchtivantinib

ArQule and Daiichi Sankyo drop tivantinib trial in NSCLC

03-10-2012

USA-based drug developer ArQule (Nasdaq: ARQL) saw its shares plunge 62% to $1.90 after, along with its…

ArQuleBiotechnologyDaiichi SankyoOncologyPharmaceuticalResearchtivantinib

Kyowa Hakko Kirin starts Ph III trial of ARQ 197 (tivantinib) in NSCLC patients in Asia

10-08-2011

Japanese drugmaker Kyowa Hakko Kirin (TYO: 4151) says it has initiated an international Phase III clinical…

ArQuleKyowa Hakko KirinOncologyPharmaceuticalResearchtivantinib

Back to top